Vaccine Experts Say "Too Early to Judge Moderna COVID-19 Vaccine" (Comprehensive)

[Image source=EPA Yonhap News]

[Asia Economy New York=Correspondent Baek Jong-min] Negative claims have been raised regarding the performance of the COVID-19 vaccine candidate from the U.S. biotech company Moderna. The New York stock market turned bearish following this news released just before the market closed.

According to MarketWatch on the 19th (local time), the medical media outlet Stat News reported on the 18th (local time) that experts believe the clinical trial results announced by Moderna are still insufficient.

Stat News asked vaccine experts for their opinions on Moderna's vaccine candidate, and received responses that it is difficult to make a judgment based on the information provided by the company. They criticized Moderna for disclosing very little information and noted that the released content was simple explanations rather than numerical data. The outlet emphasized that in science, numbers are more important than words.

One day earlier, Moderna announced that all 45 subjects in their clinical trial for their vaccine candidate (mRNA-1273) developed antibodies.

Following this report, Moderna's stock price on the Nasdaq market plummeted sharply near the market close, falling by as much as 10% compared to the previous day.

The overall New York stock market also reversed to a decline. The Dow Jones Industrial Average fell 1.5%, while the S&P 500 and Nasdaq dropped 1.05% and 0.54%, respectively.

This content was produced with the assistance of AI translation services.